Try our mobile app
Screener
Company
Price and
change
Revenue Growth
last / hist
EV /
LTM
EBITDA
(p75)
EV/
Sales
EBITDA LTM
/ Revenue
FCF LTM
/ Revenue
Next GAAP report
Year div-d yield
FCF Yield LTM
55.6%  /
46.8%
3.5x
4.8x
3.4x
98.7%
105.3%
..
5.6%
26.8% 
-18.3%  /
38.9%
13.9x
7.2x
0.7x
5.1%
4.5%
..
0.4%
7.1% 
40.4%  /
24.6%
4.8x
4.8x
0.5x
10.3%
7.1%
..
0.0%
10.5% 
-14.6%  /
12.8%
7x
4.8x
0.7x
9.3%
3.0%
..
4.7%
4.8% 
5.9%  /
7.5%
39.1x
33.6x
0.7x
1.9%
0.2%
2026-10-22
0.0%
0.5% 
-8.1%  /
7.4%
6.6x
4.2x
0.6x
9.3%
1.6%
..
0.6%
3.0% 
5.8%  /
4.7%
10.4x
8.8x
1.2x
11.7%
4.0%
..
0.8%
4.3% 
16.1%  /
4.3%
6.3x
5.8x
1.1x
17.1%
-21.7%
2026-11-04
0.0%
-111.8% 
33.5%  /
1.0%
14.1x
13.8x
1.9x
13.3%
-0.9%
2026-10-24
0.6%
-0.6% 
23.0%  /
-0.4%
11.7x
12.3x
1.8x
15.6%
9.8%
2026-10-28
0.6%
5.7% 
12.0%  /
-3.9%
8.1x
7.5x
0.9x
12.5%
0.3%
2026-11-04
1.8%
0.3% 
-3.4%  /
-6.1%
12.4x
8.4x
0.7x
5.4%
13.8%
..
2.0%
36.2% 
-9.7%  /
-8.6%
5.6x
6.9x
1.5x
27.4%
14.2%
..
0.0%
6.0% 
4.5%  /
-10.5%
13.5x
12.5x
0.4x
3.3%
-2.7%
..
1.0%
-9.3% 
Trending screeners:
@electric-vehicles
@saas
@cannabis-players
@china
Latin America
India
Dividends
@REITs
@adtech
@airlines
@artificial-intelligence
@auto-parts
@cloud-computing
@crypto
@cybersecurity
@e-commerce
@edtech
@finance-and-technology
@gaming
@internet-of-things
@oil-refining
@real-estate-tech
@renewable-energy
@vaccine-makers

Reviews

2026-09-14
#reports #HFFG

[HF Foods Group](https://eninvs.com/all.php?name=HFFG) (Food Distribution) reported for 2026 q2
(2026-05-12, After Market Close):

- Revenue +8.7% YoY (vs +4.7% in previous quarter and historical rate +39.0%)
- EBITDA +150% YoY (vs +300.0% in previous quarter)
- EBITDA margin 3.1% increased compared to 1.3% same period last year
- Net Debt increased by $9 mln over the past reporting period (10.1% of market cap)
- FCF (LTM) -$0 bln (negative), 16.8% of market cap
- EV/EBITDA multiple is 7.8x compared to historical level (75th percentile) of 4.3x
- EV/Sales multiple is 0.2x

2026-09-14
#reports #DHR

[Danaher](https://eninvs.com/all.php?name=DHR) ( Medical equipment manufacturer ) reported for 2026 q1
(2026-04-21, Before Market Open):

- Revenue +5.5% YoY (vs +3.7% in previous quarter and historical rate +2.6%)
- EBITDA +40% YoY (vs +5.6% in previous quarter and historical rate -1.1%)
- EBITDA margin 21.1% increased compared to 15.9% same period last year
- Net Debt increased by $9.4 bln since the start of the year (6.5% of market cap)
- FCF (LTM) +$5.2 bln (positive), 3.6% of market cap
- EV/EBITDA multiple is 28.5x compared to historical level (75th percentile) of 34.6x
- EV/Sales multiple is 6.7x

2026-09-14
#reports #CMCSA

[Comcast](https://eninvs.com/all.php?name=CMCSA) (Telecommunications company) reported for 2026 q1
(2026-04-23, Before Market Open):

- Revenue +0.2% YoY (vs -1.4% in previous quarter and historical rate +0.8%)
- EBITDA -6.9% YoY (vs -9.3% in previous quarter and historical rate +16.2%)
- EBITDA margin 29.6% decreased compared to 31.8% same period last year
- EV/EBITDA multiple is 5.6x compared to historical level (75th percentile) of 7.1x
- EV/Sales multiple is 1.7x

2026-09-14
#reports #BMY

[Bristol-Myers Squibb](https://eninvs.com/all.php?name=BMY) ( Pharmaceutical and nutritional products manufacturer ) reported for 2026 q1
(2026-04-30, Before Market Open):

- Revenue +5.7% YoY (vs +2.6% in previous quarter and historical rate +2.9%)
- EBITDA +130.5% YoY (vs +9.1% in previous quarter and historical rate +25.7%)
- EBITDA margin 31.5% increased compared to 14.5% same period last year
- Net Debt decreased by $488 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) +$8.2 bln (positive), 6.1% of market cap
- EV/EBITDA multiple is 14.2x compared to historical level (75th percentile) of 19.5x
- EV/Sales multiple is 3.4x

2026-09-14
#reports #ATLC

[Atlanticus Corporation](https://eninvs.com/all.php?name=ATLC) (Credit Services) reported for 2026 q2
(2026-05-07, After Market Close):

- Revenue +88.8% YoY (vs +97.1% in previous quarter and historical rate +36.6%)
- Net Income +61.3% YoY (vs +37.5% in previous quarter and historical rate +21.7%)
- Net Income margin 6.7% decreased compared to 7.9% same period last year
- P/E multiple is 9.3x compared to historical level (75th percentile) of 5.4x
- P/S multiple is 0.5x
- Price to book: 2.4x
2026-09-14
#reports #AQST

[Aquestive Therapeutics](https://eninvs.com/all.php?name=AQST) (Drug Manufacturers — Specialty and Generic) reported for 2026 q2
(2026-05-13, After Market Close):

- Revenue +55.6% YoY (vs 0.0% in previous quarter and historical rate +6.0%)
- EBITDA margin -57.1% increased compared to -211.1% same period last year
- Net Debt increased by $23 mln over the past reporting period (8.8% of market cap)
- FCF (LTM) -$0 bln (negative), 17.7% of market cap
- EV/Sales multiple is 4.3x

2026-09-14
#reports #APOG

[Apogee Enterprises](https://eninvs.com/all.php?name=APOG) (Building Products and Equipment) reported for [2026 q2](https://eninvs.com/press_release.php?ticker=APOG&q=2026 q2&id=958745)
(2026-04-24, Before Market Open):

- Revenue +0.6% YoY (vs +2.0% in previous quarter and historical rate -0.5%)
- EBITDA -22.5% YoY (vs -30.2% in previous quarter and historical rate +7.4%)
- EBITDA margin 9.0% decreased compared to 11.7% same period last year
- Net Debt decreased by $9 mln over the past reporting period (1.1% of market cap)
- FCF (LTM) +$0 bln (positive), 6.1% of market cap
- EV/EBITDA multiple is 8.5x compared to historical level (75th percentile) of 7.6x
- EV/Sales multiple is 0.8x

2026-09-14
#reports #APLS

[Apellis Pharmaceuticals](https://eninvs.com/all.php?name=APLS) (Therapeutic drug developer) reported for 2026 q1
(2026-05-18, Before Market Open):

- Revenue +60.5% YoY (vs -6.1% in previous quarter and historical rate +100.7%)
- EBITDA margin 10.1% increased compared to -49.7% same period last year
- Net Debt decreased by $8 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) +$0.1 bln (positive), 30.5% of market cap
- EV/EBITDA multiple is 1.4x compared to historical level (75th percentile) of 18.5x
- EV/Sales multiple is 0.3x

2026-09-14
#reports #APLE

[Apple Hospitality REIT](https://eninvs.com/all.php?name=APLE) (Hotel business) reported for 2026 q2
(2026-05-04, After Market Close):

- Revenue +4.9% YoY (vs +3.0% in previous quarter and historical rate +3.2%)
- EBITDA +3.8% YoY (vs -1.0% in previous quarter and historical rate +18.7%)
- EBITDA margin 34.2% decreased compared to 34.6% same period last year
- Net Debt decreased by $66 mln over the past reporting period (1.8% of market cap)
- FCF (LTM) +$0.2 bln (positive), 6.6% of market cap
- EV/EBITDA multiple is 11.4x compared to historical level (75th percentile) of 9.9x
- EV/Sales multiple is 3.6x

2026-09-14
#reports #APD

[Air Products and Chemicals](https://eninvs.com/all.php?name=APD) ( Gases and chemicals producer) reported for 2026 q2
(2026-04-30, Before Market Open):

- Revenue +4.6% YoY (vs +8.8% in previous quarter and historical rate -0.8%)
- EBITDA -243.6% YoY (vs +112700.0% in previous quarter and historical rate -4.7%)
- EBITDA margin -54.2% decreased compared to 39.4% same period last year
- EV/EBITDA multiple is 90.4x compared to historical level (75th percentile) of 101.5x
- EV/Sales multiple is 6.8x

2026-09-14
#reports #APAM

[Artisan Partners Asset Management](https://eninvs.com/all.php?name=APAM) (Investment management company) reported for 2026 q2
(2026-04-28, After Market Close):

- Revenue +8.8% YoY (vs +9.4% in previous quarter and historical rate +10.1%)
- Net Income +19.1% YoY (vs -4.9% in previous quarter and historical rate +12.5%)
- Net Income margin 26.3% increased compared to 24.0% same period last year
- P/E multiple is 7.9x compared to historical level (75th percentile) of 11.4x
- P/S multiple is 1.9x
- Price to book: 5x
2026-09-14
#reports #AP

[Ampco-Pittsburgh Corporation](https://eninvs.com/all.php?name=AP) (Metal Fabrication) reported for 2026 q2
(2026-05-12, After Market Close):

- Revenue -13.3% YoY (vs -1.0% in previous quarter and historical rate +1.3%)
- EBITDA +350% YoY (vs -12.5% in previous quarter and historical rate +12.9%)
- EBITDA margin 9.2% increased compared to 1.8% same period last year
- EV/Sales multiple is 0.7x

2026-09-14
#reports #AOS

[A O Smith](https://eninvs.com/all.php?name=AOS) (Water heating and water treatment equipment manufacturer) reported for 2026 q2
(2026-04-30, Before Market Open):

- Revenue +4.1% YoY (vs +4.8% in previous quarter and historical rate +1.4%)
- EBITDA -9.4% YoY (vs +0.6% in previous quarter and historical rate +28.7%)
- EBITDA margin 18.2% decreased compared to 21.0% same period last year
- Net Debt increased by $44 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) +$0.6 bln (positive), 6.7% of market cap
- EV/EBITDA multiple is 12x compared to historical level (75th percentile) of 15.6x
- EV/Sales multiple is 2.4x

2026-09-14
#reports #AON

[Aon](https://eninvs.com/all.php?name=AON) (Insurance company) reported for 2026 q2
(2026-07-24, Before Market Open):

- Revenue +2.2% YoY (vs +6.4% in previous quarter and historical rate +11.3%)
- Net Income -4.8% YoY (vs +25.6% in previous quarter and historical rate +15.1%)
- Net Income margin 13.0% decreased compared to 13.9% same period last year
- P/E multiple is 15.9x compared to historical level (75th percentile) of 27.6x
- P/S multiple is 3.6x
- Price to book: 6.7x
2026-09-14
#reports #ANIP

[ANI Pharmaceuticals](https://eninvs.com/all.php?name=ANIP) ( Specialty pharmaceutical company) reported for 2026 q2
(2026-05-08, Before Market Open):

- Revenue +35% YoY (vs +24.1% in previous quarter and historical rate +39.0%)
- EBITDA +22.4% YoY (vs +233.3% in previous quarter and historical rate +72.6%)
- EBITDA margin 22.6% decreased compared to 24.9% same period last year
- Net Debt decreased by $53 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) +$0.2 bln (positive), 15.1% of market cap
- EV/EBITDA multiple is 6.2x compared to historical level (75th percentile) of 21.9x
- EV/Sales multiple is 1.4x

2026-09-14
#reports #ANF

[Abercrombie & Fitch](https://eninvs.com/all.php?name=ANF) (Clothing and accessories stores chain ) reported for 2026 q2
(2026-05-27, Before Market Open):

- Revenue +15.5% YoY (vs -29.7% in previous quarter and historical rate +10.9%)
- EBITDA +105.4% YoY (vs -52.6% in previous quarter and historical rate +67.9%)
- EBITDA margin 24.0% increased compared to 13.5% same period last year
- EV/EBITDA multiple is 8.8x compared to historical level (75th percentile) of 10.1x
- EV/Sales multiple is 1.6x

2026-09-14
#reports #AMWL

[American Well Corporation](https://eninvs.com/all.php?name=AMWL) (Health Information Services) reported for 2026 q2
(2026-02-12, After Market Close):

- Revenue -26.8% YoY (vs -17.9% in previous quarter and historical rate -7.0%)
- EBITDA margin -5.8% increased compared to -16.9% same period last year
- EV/Sales multiple is 0.1x

2026-09-14
#reports #AMSF

[AMERISAFE](https://eninvs.com/all.php?name=AMSF) (Insurance services provider) reported for [2026 q2](https://eninvs.com/press_release.php?ticker=AMSF&q=2026 q2&id=960625)
(2026-07-21, After Market Close):

- Revenue +13.6% YoY (vs +9.6% in previous quarter and historical rate +3.5%)
- Net Income +7.1% YoY (vs -11.1% in previous quarter and historical rate -7.4%)
- Net Income margin 16.3% decreased compared to 17.3% same period last year
- P/E multiple is 10x compared to historical level (75th percentile) of 15.9x
- P/S multiple is 1.4x
- Price to book: 1.7x
2026-09-14
#reports #AMRN

[Amarin](https://eninvs.com/all.php?name=AMRN) (Biotechnology) reported for 2026 q2
(2026-02-25, Before Market Open):

- Revenue -42.5% YoY (vs +7.1% in previous quarter and historical rate -16.8%)
- EBITDA margin -28.6% decreased compared to -21.9% same period last year
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 0.4x
- EV/Sales multiple is -0.1x

2026-09-14
#reports #AMPH

[Amphastar Pharmaceuticals](https://eninvs.com/all.php?name=AMPH) (Drug Manufacturers — Specialty and Generic) reported for 2026 q2
(2026-05-07, After Market Close):

- Revenue +5.7% YoY (vs 0.0% in previous quarter and historical rate +11.7%)
- EBITDA -5.9% YoY (vs -51.1% in previous quarter and historical rate +8.0%)
- EBITDA margin 26.1% decreased compared to 29.3% same period last year
- EV/EBITDA multiple is 10.1x compared to historical level (75th percentile) of 10.5x
- EV/Sales multiple is 2x

2026-09-14
#reports #AMN

[AMN Healthcare Services](https://eninvs.com/all.php?name=AMN) (Health care workforce solutions provider ) reported for 2026 q2
(2026-05-07, After Market Close):

- Revenue -2.5% YoY (vs +87.5% in previous quarter and historical rate -9.6%)
- EBITDA +11.5% YoY (vs +15200.0% in previous quarter and historical rate -37.7%)
- EBITDA margin 8.6% increased compared to 7.5% same period last year
- EV/EBITDA multiple is 9.9x compared to historical level (75th percentile) of 60.6x
- EV/Sales multiple is 0.6x